The relation between of insulin like growth factor II and endometrial carcinoma

Background: Endometrial cancer is the most common gynecologic malignancy in the United States and the fourth most common cancer in women. The need of a soft marker that can be used with CA-125 tumor marker for early detection of endometrial cancer and to predict late stages and advanced histopathological grades and to specify the cases who will be managed by complete surgical staging including para aortic and pelvic lymphadenectomy is of great importance. The aim of the study was to evaluate the role of insulin like growth factor 2 in endometrial carcinoma and to correlate it with different histopathological grades of the disease.Methods: This study was applied on sixty patients with abnormal uterine bleeding and were divided into two groups, Group A included 30 cases of endometrial carcinoma, while Group B included 30 cases complaining of abnormal vaginal bleeding due to other causes as a control group. Serum samples were taken from all patients and estimation of IGF-2 serum levels using ElISA technique was done. Comparison of IGF-2 serum level between both groups and correlation of its levels with different histopathological grades of endometrial cancer group were done.Results: As regard comparison between both groups and ILGF2 serum level, study results demonstrated that ILGF2 levels ranged between 600.0-1440.0 ng/ml and 40.0-560.0 ng/ml with the mean of 781.33 ng/ml±196.45 and 336.0 ng/ml±212.86 for cases Group A and control Group B respectively. There was a statistically significant difference between the two studied groups regarding ILGF2 serum level (p<0.001). As regards correlation between histopathological grades and ILGF-2 serum level in cases Group A, the study revealed a strong positive correlation.Conclusions: ILGF-2 can be used as a serum marker for endometroid adenocarcinoma of the body of the uterus and to predict its higher histopathological grades.

Serum adenosine deaminase activity and its isoenzyme pattern as a marker for monitoring disease activity in systemic lupus erythematosus patients

Total serum ADA activity [tADA] and the isoenzyme pattern of ADA were analyzed by the HPLC method using a specific inhibitor of ADA1, erythro-9-[2-hydroxy-3-nonyl] adenine [EHNA]. Systemic lupus erythematosus activity was assessed by SLE disease activity index [SLEDAI]. Our data show that serum tADA activity was significantly increased in patients with active SLE compared to healthy controls. The isoenzyme analyses showed that the increased tADA activity in these patients was mainly due to increased ADA2 activity. In patients with active SLE, strong correlations were found between serum and ADA and ADA2 activities. Moreover, serum tADA activity was strongly correlated to ESR and to anti-ds-DNA levels. Furthermore, serum ADA2 activity was strongly correlated to ESR